Catalent

Last updated

Catalent, Inc.
Type Public company
IndustryPharmaceuticals
Predecessor Cardinal Health PTS
Founded2007
Headquarters Somerset, New Jersey, U.S.
Number of locations
49 (2020) [1]
Key people

Alessandro Maselli
(President, CEO & Director),
Matti Masanovich
(CFO)
ServicesDrug pre-formulation, formulation, analytical testing, clinical and commercial manufacturing, clinical packaging and supply chain, regulatory consulting
RevenueIncrease2.svg US$4.828 Billion (Fiscal Year Ended June 30, 2022) [2]
Decrease2.svg US$0.756 Billion (Fiscal Year Ended June 30, 2022) [2]
Decrease2.svg US$0.519 Billion (Fiscal Year Ended June 30, 2022) [2]
Total assets Increase2.svg US$10.507 Billion (Fiscal Year Ended June 30, 2022) [2]
Total equity Increase2.svg US$4.795 Billion (Fiscal Year Ended June 30, 2022) [2]
Number of employees
14,000 (2020)
Website catalent.com

Catalent, Inc. (Catalent Pharma Solutions) is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people, [3] including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue. [1]

Contents

Catalent was formed in April 2007 when affiliates of the Blackstone Group L.P. acquired the core of the pharmaceutical technologies and services (PTS) segment of Cardinal Health, Inc. [4] Cardinal Health created PTS through a series of acquisitions starting with R.P. Scherer Corporation in 1998. [5]

In 2014, Catalent became a public company, listed on the New York Stock Exchange.

History

Before 2007

In 1996, Cardinal Health acquired PCI (Headquarters: Philadelphia, Pennsylvania). [6] PCI (Packaging Coordinators Inc.) is a pharmaceutical contract packing service for commercial and clinical packaging. [7]

In 1998, Cardinal Health acquired R.P. Scherer Corporation (Headquarters: Troy, Michigan). [8] Robert Pauli Scherer founded the R.P. Scherer Corporation to commercialize his innovation of softgel encapsulation using the rotary die production process. [9] The following year, in 1999, Cardinal Health acquired Automatic Liquid Packaging, Inc. (Headquarters: Woodstock, Ill.), [6] whose Blow-Fill-Seal Technology allowed Cardinal to enter the sterile product market. [9]

In 2001, Cardinal Health acquired International Processing Corporation, a company that was renowned for its expertise in oral modified-release dosage form development and manufacturing. In 2002, Cardinal Health acquired Magellan Laboratories Inc., a company that specialized in product development expertise. [6] In 2003, Cardinal Health acquired Gala Biotech (Headquarters: Madison, Wisconsin). [6] In the same year, Cardinal Health also acquired Intercare Group PLC, broadening its global capabilities in Europe. [6]

From 2004 to 2006, Cardinal Health further expanded its reach in biotechnology and pharmaceutical markets through multiple acquisitions. [6]

Formation of Catalent in 2007

In 2007, the pharmaceutical technologies and services segment of Cardinal Health was purchased by Blackstone Group and re-branded as Catalent Pharma Solutions. [4]

After 2007 and initial public offering-2019

In 2012, Catalent acquired Aptuit, a clinical supply company. As part of the deal, Catalent gained three sites in the US, two in the UK, and one in Singapore. [10] Catalent also acquired all remaining shares for the R.P Scherer site in Eberbach, Germany. [8] [11] [12] In 2013, Catalent continued the global expansion of its Softgel capabilities through a joint venture with Zhejiang Jaing Yuan Tang Biotechnology Co, a China-based company, and Relthy Laboratories in Brazil. [13]

Catalent announced its initial public offering in July 2014. After raising more than $870 million, Catalent became a publicly traded company on the New York Stock Exchange (NYSE). [14] The company priced its 42.5 million shares of common stock at $20.50 apiece, with a market capitalization of $2.4 billion. The shares began trading on the NYSE on 31 July 2014, under the ticker symbol CTLT. [14]

In November 2014, Catalent announced it had acquired Micron Technologies, a provider of particle size engineering technologies. [15] The acquisition allowed Catalent to expand its portfolio of drug delivery technologies. [15]

In 2016, Catalent licensed the anti-body drug conjugate (ADC) to Triphase Accelerator to help with oncology development, [16] and bought Pharmatek Laboratories to add spray drying to their manufacturing capabilities. [17] In September 2017, Catalent agreed to acquire Cook Pharmica for $950 million, allowing Catalent to expand their biologic manufacturing. [18] In July 2018, Catalent extended their work with Juniper Pharmaceuticals with a $133 million deal. [19]

Alessandro Maselli was appointed as president and chief operating officer in 2019, a newly created position within Catalent. [20] In March, 2019, Catalent invested more than $27 million to commercialize Zydis Ultra. The investment includes new Zydis lines; changes to one of their facilities in Swindon, UK; and a custom suite for commercial equipment. [21] Later in 2019, Catalent partnered with GB Sciences to develop a cannabinoid-derived medicine for Parkinson's disease utilizing the Zydis delivery method. [22]

In April 2019, Catalent agreed to acquire Paragon Bioservices Inc for $1.2 billion to expand its gene-therapy manufacturing capabilities. [23] The deal was completed in May 2019 and included an agreement with Sarepta Therapeutics, a gene therapy manufacturer. [24] As of October 2019, Paragon's employee numbers have almost doubled since the April acquisition. [25]

In June 2019, Catalent acquired Bristol-Myers' European launch pad to expand its global CDMO. [26]

2020-present

In January 2020, Catalent purchased a manufacturing facility located in Anagni, Italy, from Bristol-Myers Squibb, to manufacture and package biologic and oral solid dose products for multiple companies. [27] In February 2020, Catalent agreed to acquire MaSTherCell, a Belgian gene and cell therapy manufacturer, for $315 million. The acquisition allows Catalent to expand into cell therapy development. [28] [29]

In 2020, Catalent partnered with multiple drugmakers, including Pfizer, Johnson & Johnson, [30] AstraZeneca, [31] and Moderna [32] to provide manufacturing, vial filling and packaging capabilities for COVID-19 vaccine candidates. [33] [34] In the partnership with AstraZeneca, Catalent will provide manufacturing from its Maryland facility and vial filling and packaging from its Italian facility. [35] Catalent also partnered with ViralClear to manufacture a COVID-19 treatment candidate at Catalent's St. Petersburg facility. [36] Also in 2021, Catalent acquired German gene therapy development firm Rheincell Therapeutics. [37]

In August 2021, Catalent announced plans to acquire nutritional supplement company Bettera Holdings LLC for $1 billion. The deal will allow Catalent to manufacture vitamins, minerals and supplements in gummy form. [38]

In October 2021, Catalent opened a 6,000 square-meter clinical supply facility in Shiga, Japan. [39]

In October 2022, Catalent announced a $12M expansion at a Kansas City, MO facility. [40]

January 2023, Catalent partnered with Sarepta Therapeutics to manufacture delandistrogene moxeparvovec (SRP-9001). Sarepta's most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy (DMD). [41] [42] [43]

Financials

Annual Financial Table [1]
#2016201720182019202020212022
Sales/Revenue1.85B2.08B2.46B2.52B3.09B3.998B4.828B
Total Current Assets3.09B2.45B4.53B6.18B7.78B9.112B10.507B
Net Operating Cash Flow155.3M299.5M374.5M247.7M440.3M0.585B0.519B

Related Research Articles

<span class="mw-page-title-main">Pfizer</span> American multinational pharmaceutical and biotechnology corporation

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).

<span class="mw-page-title-main">Novartis</span> Swiss-American multinational pharmaceutical corporation

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.

<span class="mw-page-title-main">Takeda Pharmaceutical Company</span> Japanese pharmaceutical company

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.

<span class="mw-page-title-main">Roche</span> Swiss multinational healthcare company

F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally.

<span class="mw-page-title-main">Amgen</span> American multinational biopharmaceutical company

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen's Thousand Oaks staff in 2022 numbered approximately 5,000 and included hundreds of scientists, making Amgen the largest employer in Ventura County. As of 2022, Amgen has approximately 24,000 staff in total.

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.

<span class="mw-page-title-main">Zydis</span>

Zydis is a technology used to manufacture orally disintegrating tablets developed by R.P. Scherer Corporation. Zydis tablets dissolve in the mouth within 3 seconds.

Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products, outsourcing services, and animals for research and development in the pharmaceutical industry and offers support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

<span class="mw-page-title-main">Astellas Pharma</span> Japanese pharmaceutical company

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd.. On February 5, 2020, the company announced management changes effective from April 1, 2020.

<span class="mw-page-title-main">Teva Pharmaceuticals</span> Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals. Teva Pharmaceuticals was the largest generic drug manufacturer, when it was surpassed briefly by US-based Pfizer. Teva regained its market leader position once Pfizer spun off its generic drug division in a merger with Mylan, forming the new company Viatris at the end of 2020. Overall, Teva is the 18th largest pharmaceutical company in the world.

<span class="mw-page-title-main">Daiichi Sankyo</span> Japanese pharmaceutical company

Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent.

<span class="mw-page-title-main">Cambrex Corporation</span> American pharmaceutical company

Cambrex Corporation is a Contract Development Manufacturing Organisation (CDMO) that provides drug substance, drug product and analytical services across the entire drug lifecycle, as well as active pharmaceutical ingredients (APIs). With over 2,200 employees in 7 countries across 13 locations, Cambrex operates in branded and generic markets for API and dosage form development and manufacturing.

<span class="mw-page-title-main">Softgel</span> Gelatin-based oral dosage form

A softgel is an oral dosage form for medicine in the form of a specialized capsule. They consist of a gelatin based shell surrounding a liquid fill. Softgel shells are a combination of gelatin, water, opacifier and a plasticiser such as glycerin or sorbitol.

<span class="mw-page-title-main">Lonza Group</span> Swiss pharmaceutical and biotech company

Lonza Group is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland. The company provides product development services to the pharmaceutical and biologic industries, including custom manufacturing of biopharmaceuticals and detection systems and services for the bioscience sector.

A contract manufacturing organization (CMO), more recently referred to as a contract development and manufacturing organization (CDMO) to avoid the acronym confusion of Chief Medical Officer or Clinical Monitoring Organization in the pharma industry, is a company that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug development through drug manufacturing. This allows major pharmaceutical companies to outsource those aspects of the business, which can help with scalability or can allow the major company to focus on drug discovery and drug marketing instead.

WuXi AppTec is a global pharmaceutical, biopharmaceutical, and medical device company.

<span class="mw-page-title-main">Oxford Biomedica</span> BioTech Company

Oxford Biomedica is a gene and cell therapy company specialising in the development of gene-based medicines. It is listed on the London Stock Exchange.

<span class="mw-page-title-main">Merck & Co.</span> American multinational pharmaceutical company

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.

References

  1. 1 2 3 "Catalent 2022 Annual Report" (PDF). Catalent Investors. Retrieved 5 June 2023.
  2. 1 2 3 4 5 "Catalent, Inc. 2020 Annual Report" (PDF). s23.q4cdn.com. 30 June 2021. Archived from the original (PDF) on 10 October 2021. Retrieved 10 October 2021.
  3. ↑ "Catalent Boosts Supply Chain Transparency in Response to COVID-19 Manufacturing Urgency". BioSpace. Archived from the original on 1 November 2020. Retrieved 8 November 2020.
  4. 1 2 "Cardinal Health Completes Sale of Pharmaceutical Technologies and Services Segment to The Blackstone Group". Dublin, Ohio: Blackstone Group. 10 April 2007.
  5. ↑ "Cardinal Health Agrees to Acquire Scherer for $2.07 Billion in Stock". The Wall Street Journal. 19 May 1998. Retrieved 2 December 2019.
  6. 1 2 3 4 5 6 "Cardinal Health's timeline -- CardinalHealth.com". CardinalHealth.com. Archived from the original on 11 April 2015. Retrieved 7 April 2015.
  7. ↑ "PCI leads the market in healthcare packaging solutions". PCI Services. Retrieved 7 April 2015.
  8. 1 2 "Catalent completes acquisition of R P Scherer Eberbach". Manufacturing Chemist. 1 March 2012. Retrieved 7 April 2015.
  9. 1 2 Kuehn, Steven (6 October 2014). "Container Innovation's Prairie Home". Pharmaceutical Manufacturing. Retrieved 7 April 2015.
  10. ↑ "Catalent completes Aptuit deal". BioPharma-reporter.com. 20 February 2012. Retrieved 7 April 2015.
  11. ↑ Wasserman, Robert (8 September 2016). "2 big companies and 1 small one to target in the pharma/biotech space". TheStreet. Retrieved 9 July 2019.
  12. ↑ "Gelita and R.P. Scherer End 60 Year Joint Venture". .foodingredientsfirst.com/. Retrieved 9 July 2019.
  13. ↑ Stanton, Dan (10 October 2013). "Catalent's Brazilian acquisition supports global softgel strategy". inPharma-technologist.com. Retrieved 7 April 2015.
  14. 1 2 "Catalent Issues Initial Public Offering". No. 8. PharmTech.com. Pharmaceutical Technology Sourcing and Management. 4 August 2014. Retrieved 7 April 2015.
  15. 1 2 "Catalent Acquires Micron Technologies, Adds Particle Engineering Capabilities to Portfolio". Pharmtech. 13 November 2014.
  16. ↑ "Catalent out-licenses ADC to Triphase". BioPharma Dive. Retrieved 4 October 2019.
  17. ↑ "Catalent Buys Pharmatek and Lands Spray Drying Technology". Pharmaceutical Investing News. 14 September 2016.
  18. ↑ "Catalent targets biologics with Cook Pharmica acquisition". Pharmaceutical Commerce. Pharmaceutical Commerce - January/February 2009. 19 September 2017. Retrieved 21 November 2019.
  19. ↑ "Catalent extends expansion with $133M deal for Juniper Pharmaceuticals". Fierce Pharma. 3 July 2018. Retrieved 16 August 2019.
  20. ↑ "Catalent Names Alessandro Maselli President and Chief Operating Officer". finance.yahoo.com. Retrieved 19 February 2019.
  21. ↑ "Catalent Invests in Zydis Ultra Commercialization". pharmtech.com. 20 March 2019.
  22. ↑ "Wellness products take off in the growing recreational cannabis market". Marijuana Business Magazine. 1 October 2019. Archived from the original on 9 December 2019. Retrieved 9 December 2019.
  23. ↑ Hopkins, Kimberly Chin and Jared S. (15 April 2019). "Catalent to Buy Paragon Bioservices for $1.2 Billion". Wall Street Journal. Retrieved 1 November 2019.
  24. ↑ "Catalent's new prize, Paragon, adding capacity to make Sarepta gene therapies". Fierce Pharma. 21 May 2019. Retrieved 26 November 2019.
  25. ↑ "Paragon growing quickly toward 1,000 employees after Catalent acquisition". Baltimore Business Journal. 17 October 2019. Archived from the original on 29 October 2020. Retrieved 23 December 2019.
  26. ↑ "'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops". Endpoints News. Retrieved 18 October 2019.
  27. ↑ "Bristol-Myers offloads manufacturing plant to Catalent". Outsourcing-Pharma. 13 January 2020.
  28. ↑ "Catalent laying out $315M to snatch another gene therapy CDMO". FiercePharma. Retrieved 3 February 2020.
  29. ↑ "Catalent adds to regenerative therapy portfolio with $315m acquisition". Manufacturing Chemist. 3 February 2020.
  30. ↑ "Pfizer to outsource some drug production, focus on coronavirus vaccine". CNBC. 9 May 2020. Retrieved 16 June 2020.
  31. ↑ "AstraZeneca Picks Catalent for Packaging, Supplying Potential COVID-19 Vaccine". The New York Times. 15 June 2020. Retrieved 16 June 2020.
  32. ↑ "Moderna Is the Latest Coronavirus Vaccine Partner for Catalent". Barrons. Archived from the original on 25 June 2020. Retrieved 7 July 2020.
  33. ↑ "'Vaccine Nationalism': A New Dynamic in the Race to Quash Coronavirus". The Wall Street Journal. 27 May 2020. Retrieved 16 June 2020.
  34. ↑ "Vaccine makers face biggest medical manufacturing challenge in history". Reuters. 25 June 2020.
  35. ↑ "AstraZeneca taps Catalent Inc. to manufacture Covid-19 vaccine candidate in Maryland". Baltimore Business Journal. 26 August 2020. Retrieved 24 September 2020.
  36. ↑ "Manufacturer to help develop potential Covid treatment at St. Pete facility". Tampa Bay Business Journal. Retrieved 17 July 2020.
  37. ↑ "Catalent Finalizes RheinCell Therapeutics Acquisition". BioPharm International. 6 August 2021. Archived from the original on 9 August 2021.
  38. ↑ Hopkins, Jared S. (30 August 2021). "WSJ News Exclusive | Catalent to Buy Supplement Maker Bettera Holdings for $1 Billion". Wall Street Journal. ISSN   0099-9660 . Retrieved 30 August 2021.
  39. ↑ "Catalent's Momentum Continues with Up to 600 New Jobs Being Added". BioSpace. Retrieved 7 January 2022.
  40. ↑ "Catalent Announces $12 Million Expansion Program at Kansas City Facility". Contract Pharma. Retrieved 2 December 2022.
  41. ↑ Keenan, Joseph (5 January 2023). "Catalent inks deal to manufacture Sarepta's DMD gene therapy". Fierce Pharma. Retrieved 24 January 2023.
  42. ↑ "Sarepta marches forward with its potential DMD gene therapy and an expanded Catalent manufacturing deal". Endpoints News. Retrieved 24 January 2023.
  43. ↑ "Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate". www.businesswire.com. 5 January 2023. Retrieved 24 January 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.